This e-learning course discusses managing non-metastatic castration-resistant prostate cancer (nmCRPC) and the implications of new imaging modalities. The course considers the application of conventional imaging vs. new imaging modalities and the potential impact of next-generation imaging on treatment options.
Two alternative approaches are presented:
- Delay time to systemic therapy
- Use systemic medications sooner
The SHARE Communication Framework Supporting Physicians In Shared Decision-Making With Patients Treated For Metastatic Castration Resistant Prostate Cancer (mCRPC)
This e-learning demonstrates what you need to explain to your patients requiring treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC) and how to confidently communicate these messages for an optimal physician-patient interaction.
This e-learning course discusses treatment sequencing for metastatic castration resistant prostate cancer (mCRPC) patients within the changing landscape of metastatic hormone sensitive prostate cancer (mHSPC).
Recent studies of the next generation androgen receptor signalling inhibitors (ARIs) provide exciting data regarding potential future treatment options for metastatic hormone sensitive prostate cancer (mHSPC) patients. This e-learning reviews the data from recent trials and considers the quality of life and cost considerations of such treatments. The course also considers the benefit of these therapies being added to existing treatment with docetaxel and ADT.